Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1-3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1-4), platelet derived growth factor receptor α (PDGFRα), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Research works printed but not linked: 1
- 2002, Cancer Research, 62, 5749
Cited by
Items 101–200 of 505
Zhang, Q., Liu, H., Wang, H., Lü, M., Miao, Y., Ding, J., Li, H., Gao, X., Sun, S., & Zheng, J. (2019) · PubMed Central · Cited by 48
Zheng, X., Xu, Z., Ji, Q., Ge, M., Shi, F., Qin, J., Wang, F., Chen, G., Zhang, Y., Huang, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0761 · Cited by 48
French, J. D., Haugen, B. R., Worden, F. P., Bowles, D. W., Gianoukakis, A. G., Konda, B., Dadu, R., Sherman, E. J., McCue, S. A., Foster, N. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3417 · Cited by 47
Welland, S., Leyh, C., Finkelmeier, F., Jefremow, A., Shmanko, K., Gonzalez-Carmona, M. A., Kandulski, A., Jeliazkova, P., Best, J., Fründt, T., et al. (2022) · Liver Cancer · doi:10.1159/000521746 · Cited by 47
Lenvatinib in Advanced Hepatocellular Carcinoma
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000479573 · Cited by 46
Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses
Gheysen, L., Sven, S., & Journé, F. (2020) · Cells · doi:10.3390/cells9040830 · Cited by 46
Nagahama, M., Ozeki, T., Suzuki, A., Sugino, K., Niioka, T., Ito, K., & Miura, M. (2019) · Medical Oncology · doi:10.1007/s12032-019-1263-3 · Cited by 46
Zhang, P., Sun, H., Wen, P., Wang, Y., Cui, Y., & Wu, J. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.12.001 · Cited by 46
Saha, D., Ryan, K. R., Lakkaniga, N. R., Acharya, B., Garcia, N. G., Smith, E. L., & Frett, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02167 · Cited by 45
Burgio, V., Iavarone, M. A., Costanzo, G. G. D., Marra, F., Lonardi, S., Tamburini, E., Piscaglia, F., Masi, G., Celsa, C., Foschi, F. G., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s330195 · Cited by 45
Lenvatinib: A Review in Refractory Thyroid Cancer
Frampton, J. E. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0416-3 · Cited by 45
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
da Costa, R. B., Giles, F. J., Carneiro, B. A., Kaplan, J. B., Agulnik, M., Pai, S. G., Chae, Y. K., Kopp, P. A., Chandra, S., & Garrett, H. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s93459 · Cited by 44
The treatment landscape in thyroid cancer: a focus on cabozantinib
Cabanillas, M. E., & Weitzman, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s68373 · Cited by 44
Elrazaz, E. Z., Serya, R. A. T., Ismail, N. S. M., Albohy, A., Ella, D. A. A. E., & Abouzid, K. A. M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105019 · Cited by 44
Current Progress of Ferroptosis Study in Hepatocellular Carcinoma
Zhu, X., Sha, X., Zang, Y., Ren, Q., Zhang, S., Ma, D., Wang, L., Yao, J., Zhou, X. Y., Yu, L., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.96014 · Cited by 43
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
Maeda, T., Kanzaki, H., Chiba, T., Ao, J., Kanayama, K., Maruta, S., Kusakabe, Y., Saito, T., Kobayashi, K., Kiyono, S., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6322-9 · Cited by 43
Zhao, Z., Song, J., Zhang, D., Wu, F., Tu, J., & Ji, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118642 · Cited by 43
Optimal management of patients with hepatocellular carcinoma treated with lenvatinib
Ikeda, M., Kobayashi, M., Tahara, M., & Kaneko, S. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1530212 · Cited by 43
Han, T., Zheng, H., Zhang, J., Yang, P., Li, H., Cheng, Z., Xiang, D., & Wang, R. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04652-9 · Cited by 42
Clinical guidance for radioiodine refractory differentiated thyroid cancer
Gild, M. L., Topliss, D. J., Learoyd, D., Parnis, F. X., Tie, J., Hughes, B. G. M., Walsh, J. P., McLeod, D. S. A., Clifton-Bligh, R. J., & Robinson, B. G. (2017) · Clinical Endocrinology · doi:10.1111/cen.13508 · Cited by 42
Kudo, M. (2021) · Liver Cancer · doi:10.1159/000514312 · Cited by 41
The action and resistance mechanisms of Lenvatinib in liver cancer
Buttell, A., & Qiu, W. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23625 · Cited by 40
Rendl, G., Sipos, B., Becherer, A., Sorko, S., Trummer, C., Raderer, M., Hitzl, W., Ardelt, M. A., Gallowitsch, H. J., & Pirich, C. (2020) · International Journal of Endocrinology · doi:10.1155/2020/8834148 · Cited by 40
Carlessi, R., Köhn‐Gaone, J., Olynyk, J. K., & Tirnitz‐Parker, J. E. E. (2019) · Codon Publications eBooks · doi:10.15586/hepatocellularcarcinoma.2019 · Cited by 39
Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma
Zhou, K., & Fountzilas, C. K. (2019) · Cancers · doi:10.3390/cancers11060861 · Cited by 39
Hatanaka, T., Kakizaki, S., Nagashima, T., Namikawa, M., Tojima, H., Shimada, Y., Takizawa, D., Naganuma, A., Arai, H., Sato, K., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13460 · Cited by 39
Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma
Masaki, C., Sugino, K., Saito, N., Saito, Y., Tanaka, T., Ogimi, Y., Maeda, T., Osaku, T., Akaishi, J., Hames, K. Y., et al. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0104 · Cited by 39
Staub, Y., Nishiyama, A., Suga, Y., FUJITA, M., Matsushita, R., & Yano, S. (2019) · Anticancer Research · doi:10.21873/anticanres.13537 · Cited by 39
Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
Girardi, D. M., Sousa, L. P., Miranda, T. A., Haum, F. N. C., Pereira, G. C. D. B., & Pereira, A. A. L. (2023) · Cancers · doi:10.3390/cancers15061680 · Cited by 39
Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma
Koizumi, Y., Hirooka, M., Hiraoka, A., Ochi, H., Tanaka, T., Yukimoto, A., Imai, Y., Watanabe, T., Yoshida, O., Miyake, T., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0140 · Cited by 38
Animal models of medullary thyroid cancer: state of the art and view to the future
Vitale, G., Gaudenzi, G., Circelli, L., Manzoni, M. F., Bassi, A. L., Fioritti, N., Faggiano, A., Colao, A., & _, _. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0399 · Cited by 36
Liu, J.-W., Chen, C., Loh, E., Chu, C.-C., Wang, M.-Y., Ouyang, H.-J., Chang, Y.-T., Zhuang, W.-Z., Chou, C.-W., Huang, D.-J., et al. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1368466 · Cited by 36
Response to Lenvatinib in Children with Papillary Thyroid Carcinoma
Mahajan, P., Dawrant, J., Kheradpour, A., Quintanilla, N., López, M. E., Orth, R. C., Athanassaki, I. D., & Venkatramani, R. (2018) · Thyroid · doi:10.1089/thy.2018.0064 · Cited by 36
Prete, A., Matrone, A., Gambale, C., Torregrossa, L., Minaldi, E., Romei, C., Ciampi, R., Molinaro, E., & Elisei, R. (2021) · Cancers · doi:10.3390/cancers13133200 · Cited by 35
Takeda, H., Nishijima, N., Nasu, A., Komekado, H., Kita, R., Kimura, T., Kudo, M., & Osaki, Y. (2019) · Hepatology Research · doi:10.1111/hepr.13294 · Cited by 35
Self-citationKuorda, H., Abe, T., Fujiwara, Y., Okamoto, T., Yonezawa, M., Sato, H., Endo, K., Oikawa, T., Sawara, K., & Takikawa, Y. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i19.2365 · Cited by 35
Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
Shi, T., Iwama, H., Fujita, K., Kobara, H., Nishiyama, N., Fujihara, S., Goda, Y., Yoneyama, H., Morishita, A., Tani, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313071 · Cited by 34
HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation
Yan, S., Chen, L., Zhuang, H., Yang, H., Yang, Y., Zhang, N., & Liu, R. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.93375 · Cited by 34
Ao, J., Chiba, T., Shibata, S., Kurosugi, A., Qiang, N., Ma, Y., Kan, M., Iwanaga, T., Sakuma, T., Kanzaki, H., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.097 · Cited by 34
Shimose, S., Hiraoka, A., Gardini, A. C., Tsutsumi, T., Nakano, D., Iwamoto, H., Tada, F., Rimini, M., Tanaka, M., Torimura, T., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13843 · Cited by 34
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin
Fallahi, P., Ferrari, S. M., Elia, G., Ragusa, F., Patrizio, A., Paparo, S. R., Marone, G., Galdiero, M. R., Guglielmi, G., Foddis, R., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.013 · Cited by 33
Dietary 2-deoxy-D-glucose impairs tumour growth and metastasis by inhibiting angiogenesis
Singh, S. P., Pandey, S., Chawla, A. S., Bhatt, A. N., Roy, B. G., Saluja, D., & Dwarakanath, B. S. R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.005 · Cited by 33
Huynh, J. C., Cho, M. T., Kim, E. J.-H., Ren, M., Ramji, Z., & Vogel, A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221116608 · Cited by 33
Lenvatinib in Advanced, Radioactive Iodine–Refractory, Differentiated Thyroid Carcinoma
Yeung, K. T., & Cohen, E. E. W. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0923 · Cited by 33
Hata, K., Suetsugu, K., Egashira, N., Makihara, Y., Itoh, S., Yoshizumi, T., Tanaka, M., Kohjima, M., Watanabe, H., Masuda, S., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04178-x · Cited by 33
Mei, Z., Gao, X., Pan, C., Wu, Q., Wang, S., Qian, J., Xu, Z., Xu, K., Zhou, L., & Zhen, S. (2023) · Cancer Science · doi:10.1111/cas.15719 · Cited by 32
Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas
Napolitano, A., Ostler, A., Jones, R. L., & Huang, P. H. (2021) · Cells · doi:10.3390/cells10061533 · Cited by 32
Zhu, J., Fang, P., Wang, C., Gu, M., Pan, B., Guo, W., Yang, X., & Wang, B. (2021) · Cancer Medicine · doi:10.1002/cam4.4312 · Cited by 32
Gardini, A. C., Puzzoni, M., Montagnani, F., Marisi, G., Tamburini, E., Cucchetti, A., Solaini, L., Foschi, F. G., Conti, F., Ercolani, G., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s192572 · Cited by 32
Hidaka, H., Uojima, H., Nakazawa, T., Shao, X., Hara, Y., Iwasaki, S., Wada, N., Kubota, K., Tanaka, Y., Shibuya, A., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13531 · Cited by 32
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Movva, S., Seier, K. P., Avutu, V., Banks, L. B., Chan, J. E., Chi, P., Dickson, M. A., Gounder, M. M., Kelly, C. M., Keohan, M. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2519 · Cited by 31
Takagi, H., Kaji, K., Nishimura, N., Ishida, K., Ogawa, H., Takaya, H., Kawaratani, H., Moriya, K., Namisaki, T., Akahane, T., et al. (2021) · Cells · doi:10.3390/cells10030575 · Cited by 31
Girardi, D. M., Pacifico, J. P. M., de Amorim, F. P. L. G., Fernandes, G. D. S., Teixeira, M. C., & Pereira, A. A. L. (2020) · Pharmaceuticals · doi:10.3390/ph14010028 · Cited by 31
Ferrari, S. M., Motta, C. L., Elia, G., Ragusa, F., Ruffilli, I., Quattrini, L., Paparo, S. R., Piaggi, S., Patrizio, A., Ulisse, S., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00764 · Cited by 31
Wang, R., Yamada, T., Arai, S., Fukuda, K., Taniguchi, H., Tanimoto, A., Nishiyama, A., Takeuchi, S., Yamashita, K., Ohtsubo, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0695 · Cited by 31
Self-citationHamieh, L., Beck, R. L., Le, V. H., & Hsieh, J. J.-D. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.03.003 · Cited by 30
Yi, D., Zhang, D., & He, J. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1995129 · Cited by 30
Kiyota, N., Tahara, M., Robinson, B. G., Schlumberger, M. J., Sherman, S. I., Leboulleux, S., Lee, E. K., Suzuki, T., Ren, M., Fushimi, K., et al. (2022) · Cancer · doi:10.1002/cncr.34181 · Cited by 30
Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes
Chavda, V. P., Zajac, K. K., Gunn, J., Balar, P. C., Khadela, A. D., Vaghela, D. A., Soni, S., Ashby, C. R., & Tiwari, A. K. (2023) · Cancer Reports · doi:10.1002/cnr2.1821 · Cited by 29
Li, L., Wen, Q., & Ding, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.905520 · Cited by 33
Tomonari, T., Tani, J., Sato, Y., Tanaka, H., Tanaka, T., Taniguchi, T., Kawano, Y., Morishita, A., Okamoto, K., Sogabe, M., et al. (2023) · Cancers · doi:10.3390/cancers15215221 · Cited by 29
Self-citationOptimal use of lenvatinib in the treatment of advanced thyroid cancer
Takahashi, S., Kiyota, N., & Tahara, M. (2017) · Cancers of the Head & Neck · doi:10.1186/s41199-017-0026-0 · Cited by 29
Kudo, M., Ueshima, K., Chiba, Y., Ogasawara, S., Obi, S., Izumi, N., Aikata, H., Nagano, H., Hatano, E., Sasaki, Y., et al. (2019) · Liver Cancer · doi:10.1159/000503032 · Cited by 29
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4381 · Cited by 28
Khaled, N. B., Møller, M., Jochheim, L. S., Leyh, C., Ehmer, U., Böttcher, K., Pinter, M., Balcar, L., Scheiner, B., Weich, A., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101065 · Cited by 28
Guo, J. F., Zhu, P., Ye, Z., Wang, M., Yang, H., Huang, S., Shu, Y., Zhang, W., Zhou, H., & Li, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.744578 · Cited by 28
Niho, S., Sato, J., Satouchi, M., Itoh, S., Okuma, Y., Mizugaki, H., Murakami, H., Fujisaka, Y., Kozuki, T., Nakamura, K., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107557 · Cited by 28
Kim, S. Y., Kim, S., Chang, H.-J., Kim, B., Lee, Y. S., Park, C. S., Park, K. C., & Chang, H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4854-z · Cited by 28
Kobayashi, K., Ogasawara, S., Maruta, S., Okubo, T., Itokawa, N., Haga, Y., Seko, Y., Moriguchi, M., Watanabe, S., Shiko, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1462 · Cited by 27
Dong, D., Shi, J.-Y., Shang, X., Liu, B., Xu, W.-L., Cui, G.-Z., & Wang, N.-Y. (2022) · Medicine · doi:10.1097/md.0000000000028680 · Cited by 27
Liu, B., Shang, X., Shi, J., Cui, G., Li, X., & Wang, N.-Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.807189 · Cited by 27
Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells
Ohno, K., Shibata, T., & Ito, K. (2022) · Cancer Science · doi:10.1111/cas.15465 · Cited by 26
Bajbouj, K., Qaisar, R., Alshura, M. A., Ibrahim, Z., Alebaji, M. B., Ani, A. W. A., Janajrah, H. M., Bilalaga, M. M., Omara, A. I., Assaleh, R. S. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084408 · Cited by 26
Bertol, B. C., Bales, E. S., Calhoun, J., Mayberry, A., Ledezma, M. L., Sams, S. B., Orlicky, D. J., Donadi, E. A., Haugen, B. R., & French, J. D. (2022) · Thyroid · doi:10.1089/thy.2021.0371 · Cited by 26
Hayato, S., Shumaker, R., Ferry, J., Binder, T. A., Dutcus, C. E., & Hussein, Z. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3687-4 · Cited by 26
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Chan, L. L., & Chan, S. L. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0114 · Cited by 25
Liu, X., Gao, X. W., Yang, Y., Yang, D., Guo, Q., Li, L., Liu, S., Cong, W., Lu, S., Hou, L., et al. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01967-0 · Cited by 24
He, M., Huang, Y., Du, Z., Lai, Z., Ouyang, H., Shen, J., Wen, D., Li, Q., Zhang, Y., Wei, W., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0060 · Cited by 24
Tyrosine Kinase Inhibitors in the Treatment of Hepatocellular Carcinoma
Khoo, T. S. W. L., Rehman, A., & Olynyk, J. K. (2019) · Codon Publications eBooks · doi:10.15586/hepatocellularcarcinoma.2019.ch7 · Cited by 24
Adachi, Y., Matsuki, M., Watanabe, H., Takase, K., Kodama, K., Matsui, J., Funahashi, Y., & Nomoto, K. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1601209 · Cited by 24
Self-citationTomonari, T., Sato, Y., Tanaka, H., Tanaka, T., Fujino, Y., Mitsui, Y., Hirao, A., Taniguchi, T., Okamoto, K., Sogabe, M., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27640 · Cited by 24
Self-citationXue, M., Wu, Y., Zhu, B., Zou, X., Fan, W., & Li, J. (2021) · PubMed Central · Cited by 23
Yano, S., Kawaoka, T., Yamasaki, S., Johira, Y., Kosaka, M., Shirane, Y., Miura, R., Amioka, K., Naruto, K., Yamaoka, K., et al. (2023) · Cancers · doi:10.3390/cancers15225406 · Cited by 23
Common carotid artery rupture during treatment with lenvatinib for anaplastic thyroid cancer
Obata, K., Sugitani, I., Ebina, A., Sugiura, Y., Toda, K., Takahashi, S., & Kawabata, K. (2016) · International Cancer Conference Journal · doi:10.1007/s13691-016-0257-7 · Cited by 23
Matsubara, N., Naito, Y., Nakano, K., Fujiwara, Y., Ikezawa, H., Yusa, W., Namiki, M., Okude, T., & Takahashi, S. (2018) · International Journal of Urology · doi:10.1111/iju.13776 · Cited by 22
Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells
Celano, M., Maggisano, V., Lepore, S. M., Sponziello, M., Pecce, V., Verrienti, A., Durante, C., Maranghi, M., Lucia, P., Bulotta, S., et al. (2019) · International Journal of Endocrinology · doi:10.1155/2019/5031696 · Cited by 22
Targeted therapies in hepatocellular carcinoma: past, present, and future
Gujarathi, R., Franses, J. W., Pillai, A., & Liao, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1432423 · Cited by 22
Kudo, M. (2021) · Liver Cancer · doi:10.1159/000514194 · Cited by 22
Deng, L., Bao, W., Zhang, B., Zhang, S., Chen, Z., Zhu, X., He, B., Wu, L., Chen, X., Deng, T., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06092-5 · Cited by 22
Boudin, L., Morvan, J.-B., Thariat, J., Métivier, D., Marcy, P. Y., & Delarbre, D. (2022) · Current Oncology · doi:10.3390/curroncol29100610 · Cited by 21
Hwang, S. Y., Lee, S. L., Liu, H., & Lee, S. S. (2023) · Liver Cancer · doi:10.1159/000534303 · Cited by 21
You, Q., Li, R., Yao, J., Zhang, Y., Sui, X. Y., Xiao, C., Zhang, J.-B., Xiao, J., Chen, H., Li, H., et al. (2024) · Medical Oncology · doi:10.1007/s12032-023-02295-0 · Cited by 21
Tsuchiya, H., Shinonaga, R., Sakaguchi, H., Kitagawa, Y., & Yoshida, K. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020071 · Cited by 21
Kuwano, A., Yada, M., Miyazaki, Y., Tanaka, K., Kurosaka, K., Ohishi, Y., Masumoto, A., & Motomura, K. (2023) · Oncology Letters · doi:10.3892/ol.2023.13845 · Cited by 21
Novel systemic therapy for hepatocellular carcinoma
Dong, Y., Liu, T., Yau, T. C. C., & Hsu, C. (2020) · Hepatology International · doi:10.1007/s12072-020-10073-7 · Cited by 21
Odagiri, N., Hai, H., Thủy, L. T. T., Dong, M. P., Suoh, M., Kotani, K., Hagihara, A., Uchida‐Kobayashi, S., Tamori, A., Enomoto, M., et al. (2020) · Cancers · doi:10.3390/cancers12082045 · Cited by 21
Zhai, L., Shi, Y., Yan, Y., Lu, A., Liu, X., Lei, L., Sun, Y., Jiang, L., Wang, X., Qian, H.-G., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.108104 · Cited by 21
Lee, C., Motzer, R. J., Glen, H., Michaelson, M. D., Larkin, J., Minoshima, Y., Kanekiyo, M., Ikezawa, H., Sachdev, P., Dutcus, C. E., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01092-0 · Cited by 21
Self-citationDuan, A., Li, H., Yu, W., Zhang, Y., & Yin, L. (2022) · Journal of Oncology · doi:10.1155/2022/4537343 · Cited by 21
Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 20
Metadata
- Authors
- Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y.
- Affiliations
- Eisai (Japan) (JP)
- Eisai (United States) (US)
- Corresponding author
- Funahashi, Yasuhiro
- ORCID
- Venue
- Journal of Thyroid Research
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 2042-0072 (ISSN-L)
- 2090-8067
- PMC
- PMC4177084
- OpenAlex
- W2094109552
- Cited by
- 475
- References
- 50
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 49 · 2023: 69 · 2022: 57 · 2021: 69 · 2020: 52 · 2019: 53 · 2018: 38 · 2017: 17 · 2016: 18 · 2015: 12 · 2014: 1
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Thyroid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- lenvatinib, thyroid cancer, angiogenesis inhibition, VEGF receptor signaling, FGFR1, RET, receptor tyrosine kinase inhibitors, anaplastic thyroid carcinoma, medullary thyroid carcinoma, differentiated thyroid cancer, xenograft models, antiproliferative activity, FRS2, KIT, PDGFRA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.